



PRESS RELEASE
For immediate release

PERCEPTRONIX TO PRESENT LUNG CANCER DETECTION TEST CLINICAL TRIAL RESULTS AT INTERNATIONAL CONFERENCE “CHEST 2005”

VANCOUVER, CANADA (October 25, 2005) – Dr. Bojana Turic and Dr. Roger Kemp of Perceptronix Medical Inc. (“Perceptronix”) will each present a paper on the detection of lung cancer by cytometric analysis at “CHEST 2005”, the 71st annual international scientific assembly of the American College of Chest Physicians being held October 29 through November 3 in Montréal, Québec, Canada. Dr. Turic, MD, Vice President and Director of Clinical and Regulatory Affairs for Perceptronix, will present:

Management of Patients at Risk of Lung Cancer Using Cytometric Assays

and Dr. Kemp, PhD, Director, Detection Products for Perceptronix, will present:

Can Early Lung Cancer be Detected from Buccal Mucosa Scrapings?

These papers will report on international clinical trials conducted on a Perceptronix platform technology to develop an inexpensive, non-invasive lung cancer detection test. Perceptronix recently submitted clinical trial data to Health Canada in support of an *in vitro* diagnostic device license application for the ClearSign™ Test of sputum for lung cancer detection, which is based on this technology. Perceptronix expects to receive a license for the ClearSign™ test from Health Canada in early 2006, after which commercial sales will commence.

In addition, Dr. Turic has been invited to participate as a panellist at a “New Developments In Lung Cancer” Press Briefing at 12:00 noon on Monday, October 31, Room 524C Palais de Congrès de Montréal.

Lung cancer, which remains the most frequent cause of cancer death in the developed world, is responsible for about 30% of all cancer deaths. In 2005, an estimated 22,200 Canadians (12,000 men; 10,200 women) will be diagnosed with lung cancer - 19,000 (10,700 men; 8,300 women) will die of it.

About Perceptronix Medical Inc.

Perceptronix (www.perceptronix.com) is a private cancer diagnostics company based in Vancouver, Canada. The company’s mission is to commercialize technologies to improve the early detection, localization, and diagnosis of malignancy, with an initial focus on lung cancer. Perceptronix was founded in June 1999 to commercialize early cancer detection technologies developed in partnership with the British Columbia Cancer Agency (www.bccancer.bc.ca), a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.

Contact:

Susan Grose
Corporate Secretary
Perceptronix Medical Inc.
Ste. 400, 555 West 8th Avenue
Vancouver, Canada V5Z 1C6
Phone: (604) 707 – 9037
info@perceptronix.com